Illicit drug use disorders are the most stigmatised health conditions worldwide, and stigma
acts as a meaningful barrier to treatment entry and treatment provision. In the context of …

Objective To compare the risk for all cause and overdose mortality in people with opioid
dependence during and after substitution treatment with methadone or buprenorphine and …

Background The opioid epidemic is a public health crisis. Medications for opioid use
disorder (MOUD) include: 1) buprenorphine, 2) methadone, and 3) extended-release …

Importance Most drug epidemics in the United States have disproportionately affected
nonwhite communities. Notably, the current opioid epidemic is heavily concentrated among …

Abstract The United States is in the midst of a national opioid epidemic. Physicians are
encouraged both to prevent and treat opioid-use disorders (OUDs). Although there are 3 …

Background Medication-assisted treatment (MAT) is an evidence-based strategy to treat
opioid use disorder (OUD). However, MAT-related stigma reduces MAT uptake, which is …

Purpose The American Society of Addiction Medicine (ASAM) developed the National
Practice Guideline for the Treatment of Opioid Use Disorder (the Practice Guideline) to …

Opioid use disorder (OUD) and its consequences are a major public health concern. The
partial agonist buprenorphine is a safe and effective treatment for OUD, but concerns about …

Background Buprenorphine is approved in many countries for the treatment of opioid use
disorder (OUD), but problems with diversion and abuse exist. There is a need to understand …

The buprenorphine receptor binding profile is unique in that it binds to all three major opioid
receptors (mu, kappa, delta), and also binds to the orphan-like receptor, the receptor for …